BTK and autoimmune disease: In addition, due its immunomodulatory effect, ibrutinib was approved by the FDA in treating the steroid-resistant chronic graft-versus-host disease (GVHD) [91]; more studies are ongoing to use the BTK inhibitors to address other autoimmune disorders [92].